Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: A Thalassemia Clinical Research Network report

Blood

Volumn 118, Issue 14, 2011, Pages 3794-3802

  Morris, Claudia R ^a   Kim, Hae Young ^b   Trachtenberg, Felicia ^b   Wood, John ^c   Quinn, Charles T ^d   Sweeters, Nancy ^a   Kwiatkowski, Janet L ^e   Thompson, Alexis A ^f   Giardina, Patricia J ^g   Boudreaux, Jeanne ^h   Olivieri, Nancy F ⁱ   Porter, John B ^j   Neufeld, Ellis J ^k   Vichinsky, Elliott P ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD TRANSFUSION; CARDIOVASCULAR MAGNETIC RESONANCE; CAUCASIAN; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; ETHNIC DIFFERENCE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS C; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SCHOOL CHILD; SMOKING; SPLENECTOMY; THALASSEMIA; TRICUSPID REGURGITANT JET VELOCITY;

EID: 80053647695     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-319152     Document Type: Article

References (59)

1. Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation. 2011;123(11):1227- 1232.
2. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl):30S-38S.
3. Gladwin M, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. (Pubitemid 38252536)
4. Maître B, Mekontso-Dessap A, Habibi A, et al. Pulmonary complications in adult sickle cell disease [in French]. Rev Mal Respir. 2011;28(2):129-137.
5. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619.
6. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1997;134(3):532-537. (Pubitemid 27431260)
7. Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1999;138(2 Pt 1):384. (Pubitemid 29379695)
8. Zakynthinos E, Vassilakopoulos T, Kaltsas P, et al. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001;56(9):737-739. (Pubitemid 32831703)
9. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73(5):359-366. (Pubitemid 39349917)
10. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with beta-thalassemia major. Ann Hematol. 2004;83(12):779-783. (Pubitemid 39485550)
11. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med. 2005;118(9):957-967. (Pubitemid 41297756)
12. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523-1530. (Pubitemid 46218775)
13. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008;177-185.
14. Aessopos A, Stamatelow G, Skoumas V, Vassilopoulos G, Mantzourani M, Loulopoulos D. Pulmonary hypertension and right heart failure in patients with B-thalassemia intermedia. Chest. 1995;107(1):50-53.
15. Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest. 1990;98(5):1138-1142. (Pubitemid 20381277)
16. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-3416.
17. Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol. 2006;81(9):670-675. (Pubitemid 44306825)
18. Hagar RW, Morris CR, Vichinsky EP. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol. 2006;133(4):433-435.
19. Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann NY Acad Sci. 2010;1202:205-213.
20. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135(2):254-263. (Pubitemid 44401624)
21. Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005;1054:481-485. (Pubitemid 43031061)
22. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
23. Borgna Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998;99(2):76-79. (Pubitemid 28119099)
24. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004:14-34.
25. Rostagno C, Prisco D, Abbate R, Poggesi L. Pulmonary hypertension associated with longstanding thrombocytosis. Chest. 1991;99(5):1303-1305.
26. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart. 2006;92(10):1467-1472. (Pubitemid 44578845)
27. Kuypers FA. Membrane lipid alterations in hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2007;2007:68-73.
28. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol. 2007;82(4):255-265. (Pubitemid 46564319)
29. Sonakul D, Pacharee P, Thakerngpol K. Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Orig Artic Ser. 1988;23(5B):157-176.
30. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011;97(8):612-622.
31. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-115. (Pubitemid 43830036)
32. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858-863. (Pubitemid 44682188)
33. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49(4):472-479. (Pubitemid 46135890)
34. Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol. 2008;140(1):104-112. (Pubitemid 350233240)
35. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83(1):19-25.
36. Lorch D, Spevack D, Little J. An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease. Acta Haematol. 2011;125(4):225-229.
37. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-1279. (Pubitemid 46905753)
38. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
39. Gladwin MT, Barst RJ, Castro OL, et al. Pulmonary hypertension and NO in sickle cell. Blood. 2010;116(5):852-854.
40. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm"for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86(2):123-154.
41. Morris CR. Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011;96(1):1-5.
42. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254-2265.
43. Bachir D, Parent F, Hajji L, et al. Prospective multicentric survey on pulmonary hypertension (PH) in adults with sickle cell disease [abstract]. Blood. 2009;114:Abstract 572.
44. Kiter G, Balci YI, Ates A, Hacioglu S, Sari I. Frequency of pulmonary hypertension in asymptomatic beta-thalassemia major patients and the role of physiological parameters in evaluation. Pediatr Hematol Oncol. 2010;27(8):597-607.
45. De Cunto G, Cardini S, Cirino G, Geppetti P, Lungarella G, Lucatelli M. Pulmonary hypertension in smoking mice over-expressing portease-activated receptor-2. Eur Respir J. 2011;37(4):823-834.
46. Schiess R, Senn O, Fischler M, et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case control study. Chest. 2010;138(5):1086-1092.
47. Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008;142(1):126-135. (Pubitemid 351783151)
48. Rodríguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861-880. (Pubitemid 39504442)
49. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med. 1996;17(1):151-169.
50. Machado R, Barst R, Yovetitch N, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated tricuspid regurgitant jet velocity and low exercise capacity. Blood. 2011;118(4):855-864.
51. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol. 1999;33(6):1662-1666.
52. Chuncharunee S, Atichartakarn V, Archararit N, et al. Prevalence and predictors of pulmonary arterial hypertension in hemoglobin E/beta-thalassemia patients [abstract]. Blood. 2009;114:795. Abstract 2015.
53. El-Beshlawy A, Youssry I, El-Saidi S, et al. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr Hematol Oncol. 2008;25(8):734-743.
54. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94(3):340-347.
55. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81-90. (Pubitemid 41002842)
56. Hahalis G, Kourakli A, Gerasimidou I, et al. Cardiac mortality in beta-thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12-year study. Eur J Heart Fail. 2009;11(12):1178-1181.
57. Cogliandro T, Derchi G, Mancuso L, et al. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown). 2008;9(5):515-525. (Pubitemid 351521635)
58. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):452-458. (Pubitemid 40592887)
59. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood. 2002;100(4):1516-1517. (Pubitemid 34864323)